Zentiva joins the Critical Medicines Alliance to enhance EU Medicine Supply

Brussels and Prague (ots/PRNewswire) - Zentiva, a Pan-European pharmaceutical
company, joined the inaugural launch of the EU's Critical Medicines Alliance,
held on April 24-25 in Brussels. This significant event, organized by DG HERA
and the Belgian Presidency, convened leaders from across the healthcare industry
to address the challenges of medicine supply resilience in the European Union.

Zentiva's CEO, Steffen Saltofte, and representatives from the pharmaceutical
industry and Medicines for Europe, the Generics association, engaged with EU
Health Ministers and discussed actionable strategies to enhance the availability
and accessibility of critical medicines throughout Europe.

Steffen Saltofte: "Our participation in the Alliance underscores our commitment.
Together, we need to ensure that essential medicines are accessible to all
people who depend on them. As generic medicines represent 70% of treatment
volume in Europe and constitute 9 out of 10 products on the critical medicines
list, our role is crucial in maintaining the continuity of healthcare services
across the continent."

DG HERA presented a Vulnerability Assessment performed on a tranche of 11 chosen
critical medicines, selected from a broader list of over 200 critical medicines.
Zentiva has seriously engaged in this assessment and believes it will be
instrumental in addressing future medicine shortages. The discussion highlighted
the need for increased manufacturing resilience.

Steffen Saltofte: "We believe that this assessment and our diligent efforts will
lead to comprehensive solutions for shortages, support the European production
of medicines, and ensure that the focus remains on substantive outcomes rather
than merely increasing administrative burdens and regulations."

Discussions also covered strategies for preventing medicine shortages, enhancing
EU manufacturing competitiveness, and ensuring equitable access across member
states.

Zentiva shared insights from its extensive experience in producing high-quality
and affordable medicines at its manufacturing sites in the Czech Republic and in
Romania that are marketed in more than 30 countries. The team of 5.000 people is
devoted to supporting the EU's vision of building a robust and sustainable
healthcare system, that ensures high-quality, accessible pharmaceutical
solutions to all people who depend on them.

About Zentiva

Zentiva is a Pan-European Company developing, manufacturing and providing
high-quality and affordable medicines to more than 100 million people in Europe.
Zentiva has 4 wholly owned manufacturing sites and a broad network of external
manufacturing partners to ensure supply security. We offer solutions in key
therapeutical areas like Cardiology & Circulation, Diabetes, Oncology,
Respiratory, CNS, and focus on expanding our portfolio in self-care. The company
is Private Equity owned, delivering sustainable double-digit growth, with an
ambitious 5-year plan for further strong growth across Europe.

We are a team of 5.000 unique talents bonded together by our responsibility to
ensure the supply of high-quality and affordable medicines to people who depend
on them every day. We want Zentiva to be a great place to work, where everyone
feels welcomed and appreciated, and can be their authentic selves contributing
to the best of their ability. We provide health and wellbeing to all
generations.

http://www.zentiva.com/

Photo -
https://mma.prnewswire.com/media/2397673/Zentiva_Critical_Medicines_Alliance.jpg

View original content to download multimedia: https://www.prnewswire.co.uk/news-
releases/zentiva-joins-the-critical-medicines-alliance-to-enhance-eu-medicine-su
pply-302127561.html

Contact:

[e-mail]; [phone]

Additional content: http://presseportal.de/pm/132270/5765969
OTS: Zentiva